张永辉 - 清华大学

个人简介

张永辉博士目前为清华大学药学院研究员。他于1996年在淮海工学院获化学工程学士学位、1999年大连理工大学获应用化学硕士学位，2002年中科院上海有机化学研究所获有机化学博士学位。2002-2003年在晟康公司任部门主管。2003年加入美国伊利诺大学香槟分校化学系博士后，并于2005年获美国心脏协会资助。2008年任化学系高级研究员。2013年入职清华大学医学院药学系（现药学院）研究员。张永辉研究员长期从事（类）胆固醇代谢领域的药学研究工作。迄今张永辉研究员已经发表了50余篇科研论文及多份专利。荣誉和奖励 Tsinghua-Janssen Investigator Award （2015） Tsinghua-Janssen Investigator Award (2014) American Heart Association Fellowship (2006) Yufeng-Hou Scholarship (1996)

研究领域

张永辉实验室一直致力于胆固醇代谢领域药学新研究方向的开拓、新药物分子的发现及新型疾病治疗方案的探索。具体研究内容包括：（1）针对KRAS突变肿瘤的联合治疗方案；（2）胆固醇代谢通路与免疫调节；（3）新型疫苗佐剂的开发；（4）免疫治疗策略研究；（5）作用于BTN3A1的新型γδ-T细胞膦抗原的发现；（6）改良的γδ-T细胞在肿瘤治疗中的应用；（7）胆固醇代谢中间体的免疫作用机制研究；（8）作用于金黄色葡萄球菌毒力因子的新型抗生素的研制；（9）作用于 PvGGPPS的新型抗疟疾小分子开发。此外，张永辉研究团队还针对IDO1及整合素家族展开了系列药学研究。

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Xia, Y., Xie, Y., Yu, Z., Xiao, H., Jiang, G., Zhou, X., Yang, Y., Li, X., Zhao, M., Li, L., Zheng, M., Han, S., Zong, Z., Meng, X., Deng, H., Ye, H., Fa, Y., Wu, H., Oldfield, E., Hu, X., Liu, W*., Shi, Y*., Zhang, Y*. The mevalonate pathway is a druggable target for vaccine adjuvant discovery. Cell , 2018, 175, 1059-1073. Yang, Y., Li, L., Zhou, X., Duan, J., Liu, W., Chen, C., Wang, L., Li, X., Cai, N., Yuan, L., Chen, J., Kang, N., Malwal, S.R., Shi, Y., Oldfield, E*., Guo, R-T*., Zhang, Y*. A structural change in butyrophilin upon phosphoantigen binding underlies phosphoantigen-mediated Vγ9Vδ 2 T cell activation. Immunity, 2019 , 50, 1043-1053. Cai, N., Han, S., Zhang, Y*. Docking complete: a step further toward the holy grail of γδ T cell biology. Immunity, 2019, 51, 781-783. Han, S., Li, X., Xia, Y., Yu, Z., Cai, N., Malwal, S., Han, X., E. Oldfield*., Zhang, Y*. Farnesyl pyrophosphate synthase as a target for drug development: discovery of natural-product-derived inhibitors and their activity in pancreatic cancer cells. J. Med. Chem. 2019, 62, 10867-10896. Malwal, S.R., Gao, J., Hu, X., Yang, Y., Liu, W., Huang, J., Ko, T-Z., Li, L., Chen, C., O’Dowd, B., Khade, R., Zhang, Y., Zhang, Y*., Oldfield, E*., Guo, R-T*. Catalytic role of conserved asparagine, glutatmine, serine, and tyrosine residues in isoprenoid biosynthesis enzymes. ACS Catalysis. 2018, 8, 4299-4312. Wang, Y., Chen, C-C., Yang, Y., Liu, W., Ko, T-P., Shang, N., Hu, X., Xie, Y., Huang, J-W., Zhang,Y*., Guo, R*. Structural insight into a novel indole prenyltransferase in hapalindole-type alkaloid biosynthesis. Biochem. Biphys. Res. Commun . 2018, 495, 1782-1788. Chen, C-C., Hu, X., Tang, X., Yang, Y., Ko, T-Z., Gao, J., Zheng, Y., Huang, J., Yu, Z., Li, L., Han, S., Cai, N., Zhang, Y*., Liu, W*., Guo, R-T*. Crystal structure of a new class of cyclases which catalyze Cope rearrangement. Angew. Chem. Int. Ed. 2018, 57, 15060-15064. Zhou, X., Gu, Y., Xiao, H., Kang, N., Xie, Y., Zhang, G., Shi, Y., Hu, X., Oldfield, E., Zhang, X*., Zhang, Y*. Combining Vγ9Vδ2 T cells with a lipophilic bisphosphonate efficiently kills activated hepatic stellate cells. Front. Immunol. 2017, 8, 1381. Xia, Y., Liu, Y-L., Xie, Y., Zhu, W., Guerra, F., Shen, S., Yeddula, N., Fischer, W., Low, W., Zhou, X., Zhang, Y*., Oldfield, E*., Verma, I. M*. A combination therapy for KRAS-driven lung adenocarcinomas using lipophilic bisphosphonates and rapamycin. Sci. Trans. Med. 2014，263ra261.